Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 3 1

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 129 Carcinoma, Non-Small-Cell Lung 101 Prostatic Neoplasms 62 Colorectal Neoplasms 49 Nasopharyngeal Carcinoma 45 Neoplasms 44 Multiple Myeloma 42 Stomach Neoplasms 35 Neoplasm Metastasis 32 Leukemia, Myeloid, Acute 32 Ovarian Neoplasms 31 Lung Neoplasms 31 Carcinoma, Hepatocellular 29 Squamous Cell Carcinoma of Head and Neck 27 Rectal Neoplasms 27 Pancreatic Neoplasms 26 Triple Negative Breast Neoplasms 25 Recurrence 25 Small Cell Lung Carcinoma 21 Brain Neoplasms 21 Esophageal Neoplasms 20 Colonic Neoplasms 20 Uterine Cervical Neoplasms 19 Lymphoma, Large B-Cell, Diffuse 17 Head and Neck Neoplasms 17 Urinary Bladder Neoplasms 16 Leukemia, Lymphocytic, Chronic, B-Cell 16 Esophageal Squamous Cell Carcinoma 16 Carcinoma, Renal Cell 16 Myasthenia Gravis 15

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recruiting × Melanoma, Cutaneous Malignant × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡